Provided by Tiger Trade Technology Pte. Ltd.

Savara Inc

5.55
-0.0400-0.72%
Volume:520.97K
Turnover:2.87M
Market Cap:1.14B
PE:-9.60
High:5.60
Open:5.60
Low:5.43
Close:5.59
52wk High:7.01
52wk Low:3.08
Shares:204.66M
Float Shares:198.20M
Volume Ratio:0.49
T/O Rate:0.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5782
EPS(LYR):-0.5344
ROE:-105.48%
ROA:-50.15%
PB:7.91
PE(LYR):-10.39

Loading ...

Savara Q1 EPS $(0.15) Misses $(0.14) Estimate

Benzinga Earnings
·
May 13

Savara Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Savara posts corporate presentation on autoimmune PAP, highlights MOLBREEVI Phase 3 data

Reuters
·
May 13

Savara Q1 Loss Widens

MT Newswires Live
·
May 13

Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss

MT Newswires Live
·
May 13

Savara Q1 net loss widens on higher R&D costs

Reuters
·
May 13

Savara Q1 FY26 net loss widens to $37.3 million; R&D expense rises 22.1% to $23.4 million

Reuters
·
May 13

BRIEF-Savara Q1 Net Income USD -37.284 Million

Reuters
·
May 13

Analysts Conflicted on These Healthcare Names: Cronos Group (CRON), Savara (SVRA) and Alkermes (ALKS)

TIPRANKS
·
May 12

Savara management to join H.C. Wainwright BioConnect Investor Conference fireside chat

Reuters
·
May 12

US High Growth Tech Stocks To Watch

Simply Wall St.
·
Apr 28

Assessing Savara (SVRA) Valuation After Recent Share Price Weakness And Ongoing Losses

Simply Wall St.
·
Apr 25

Savara Inc. : Oppenheimer Raises Target Price to $11 From $9

THOMSON REUTERS
·
Apr 24

BUZZ-India’s Mastek falls after Q4 profit declines sequentially

Reuters
·
Apr 20

Savara grants inducement equity awards to 24 new hires under 2021 plan

Reuters
·
Apr 18

DIARY-India economic, corporate events on April 17

Reuters
·
Apr 17

A Look At Savara (SVRA) Valuation After Strong 1 Year Shareholder Return

Simply Wall St.
·
Apr 16

Savara publishes corporate presentation highlighting MOLBREEVI program in autoimmune PAP

Reuters
·
Apr 16

FDA extends Savara molgramostim BLA review, pushing PDUFA date to Nov. 22, 2026

Reuters
·
Apr 16

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (Bla) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune Pap)

THOMSON REUTERS
·
Apr 16